IPP Bureau
Dr. Morepen’s diabetes awareness campaign kicks on KBC
By IPP Bureau - September 25, 2024
This initiative aims to raise awareness about the importance of monitoring blood sugar levels before indulging in sweets
Biocon Biologics announces new dermatology data to be presented at EADV Congress 2024
By IPP Bureau - September 25, 2024
These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity
AstraZeneca Pharma India to launch Tremelimumab
By IPP Bureau - September 23, 2024
Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma
WHO endorses Roche’s dual-stain cytology testing in its cervical cancer prevention guidelines
By IPP Bureau - September 23, 2024
Roche’s CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test to triage human papillomavirus (HPV)-positive cervical cancer screening test results
DevCo completes strategic capital raise for investment in Medix Biochemica
By IPP Bureau - September 23, 2024
The raised capital enables Medix Biochemica to continue execution of inorganic growth initiatives
Sightsavers India and AbbVie India host consultation on Glaucoma prevention in Bhopal
By IPP Bureau - September 23, 2024
The objectives of the campaign are to raise awareness about glaucoma, its risk factors, and the importance of regular eye check-up
Ind Swift Laboratories opens marketing office in New Delhi
By IPP Bureau - September 23, 2024
This office will be the central hub for all operations related to companies ethical pharmaceutical business
Bavarian Nordic receives EMA approval of mpox vaccine for adolescents
By IPP Bureau - September 23, 2024
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
Fermenta Biotech receives EU GMP Certification for its Dahej facility
By IPP Bureau - September 23, 2024
This approval reflects company’s unwavering commitment that the quality assurance
Pfizer and BioNTech receive positive CHMP opinion for Omicron KP.2-adapted COVID-19
By IPP Bureau - September 23, 2024
Doses will be ready to ship to applicable European Union (EU) member states as soon as possible upon European Commission (EC) authorization
Fasenra recommended for approval in the EU by CHMP for treatment of EGPA
By IPP Bureau - September 23, 2024
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
Aster DM Healthcare to launch the Rs. 220 crore Women & Children’s Hospital in Hyderabad
By IPP Bureau - September 22, 2024
The exclusive hospital will help address health complexities concerning women and children, specializing in high-end obstetrics, comprehensive gynecological, neonatal & pediatric care
Briefs: Biocon, Aarti Drugs and Glenmark Pharmaceuticals
By IPP Bureau - September 22, 2024
Glenmark Pharmaceuticals Limited has informed that the USFDA has issued Form 483 with zero observations
Pharmaceutical sector set for 8-10% revenue growth this fiscal: CRISIL
By IPP Bureau - September 20, 2024
Stable profits, low leverage to keep credit profiles comfortable
AstraZeneca Pharma India to launch Palivizumab (Synagis) in October 2024
By IPP Bureau - September 20, 2024
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease
